Clinical cure strategy for hepatitis B: immunomodulatory therapy

• Published in: Zhonghua gan zang bing za zhi Vol. 28; no. 8; p. 644
• Main Authors: Xie, Q, Ning, Q, Wang, G Q, Chen, C W, Wang, F S
• Format: Journal Article
• Language: Chinese
• Published: China 20-08-2020
• Subjects: Antiviral Agents - therapeutic use; Hepatitis B - drug therapy; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic - drug therapy; Humans; Immunomodulation; Antiviral agents; Hepatitis B, chronic; Immunotherapy
• ISSN: 1007-3418
• DOI: 10.3760/cma.j.cn501113-20200722-00410

Chronic hepatitis B virus (HBV) infection remains a major world public health problem. Current guidelines of chronic hepatitis B (CHB) suggest the clinical cure as the ideal thearapeutic goal. Although the optimization of the existing antiviral treatment can make some patients achieve clinical cure, but for most patients with chronic hepatitis B, it is difficult to achieve clinical cure according to the existing antiviral treatment plan. The medical community has begun to work together to seek new treatment strategies, especially the immune intervention measures aimed at restoring the immune response in the liver microenvironment. Notably, immune antiviral response plays a crucial role in HBV clearance, and the clinical cure of chronic hepatitis B is finally achieved through the optimized combination of antiviral and immunomodulatory drugs.